ClinicalTrials.gg
CompletedNCT06194201Updated Sep 10, 2026

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

A Phase 2 interventional study of HRS9432 and Caspofungin Acetate for Injection in Patients With Candidemia and/or Invasive Candidiasis, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS9432 in patients with candidemia and/or invasive candidiasis

02

Conditions studied

  • Patients With Candidemia and/or Invasive Candidiasis
03

In context

Candidemia

73 studies on the registry are indexed under Candidemia; 5 are open to participants now.

This study's enrollment of 61 is close to the median of 63 across 44 interventional studies indexed under Candidemia.

Browse Candidemia studies →

Lead sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females ≥18 years;
  2. Established or clinical diagnosis of candidemia and/or IC ;
  3. Present of 1 or more systemic signs attribute to candidemia and/or IC 4 days prior to randomization;
  4. Women of or male subjects whose partner is a fertile female agree to use highly effective form of from the time of signed ICF till 6 months after end of treatment;
  5. Able and willing to provide a written

Exclusion criteria

Exclusion Criteria:

  1. Any of the following forms of IC: including osteomyelitis, endocarditis or myocarditis, meningitis, endophthalmitis, or any central nervous system infection, urinary tract infection or chronic disseminated candidiasis;
  2. Severe hepatic impairment in subjects with a history of chronic cirrhosis;
  3. History of severe ataxia, tremor, or neuropathy or a diagnosis of multiple sclerosis or a movement;
  4. Laboratory abnormalities in baseline specimens obtained at screening;
  5. with clinical significance and may cause obvious safety risk to the subjects at screening;
  6. Received systemic treatment with an antifungal agent at approved doses for treatment of candidemia or IC for >48 hours;
  7. Vascular catheter or device that cannot be removed, or abscess that cannot be drained, and may be the source of candidemia or IC;
  8. A history of drug use, alcohol, or drug abuse within 1 year prior to randomization;
  9. Participated in, any other clinical study involving the administration of active or experimental medication prior to the randomization, or 5 half-lives, whichever is longer, prior to Screening;
  10. Females who are in gestation or lactating period or planned pregnancy during the study
  11. Known history of or allergic reaction to HRS9432, caspofungin etc echinocandins drugs;
  12. In the judgment of the Investigator, other reasons unsuitable for study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    HRS9432

    Drug: HRS9432

  • Active comparator
    Caspofungin Acetate for Injection

    Drug: Caspofungin Acetate for Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate overall success (mycological eradication and resolution of systemic signs attributable to candidemia and/or invasive candidiasis [IC]) of HRS9432 IV in subjects with candidemia and/or IC in the Microbiological Intent-to-treat (mITT) population

    Time frame: Day 14

Secondary outcomes

  1. Evaluate overall success (mycological eradication and resolution of systemic signs attributable to candidemia and/or IC) of HRS9432 IV in the mITT population

    Time frame: Day 5, Day 28, End of treatment(≤2 days of last dose) and End of Study (Day 56±3 days)]

  2. Evaluate clinical cure as assessed by the Investigator for HRS9432 IV in the mITT population

    Time frame: Day 5, Day 14, Day 28, End of Treatment (≤2 days of last dose) and End of Study (Day 56±3 days)

  3. Evaluate mycological success(eradication) of HRS9432 IV in the mITT population

    Time frame: Day 5, Day 14, Day 28, End of Treatment (≤2 days of last dose) and End of Study (Day 56±3 days)

  4. Evaluate All cause Mortality in the mITT population

    Time frame: Day 28 and End of Study (Day 56±3 days)

  5. The time when two consecutive negative candida cultures occurred for the first time with an interval of ≥12h in the mITT population

    Time frame: Day1 through End of Study (Day 56±3 days)

  6. Percentage of Participants with mycological recurrence in the mITT population

    Time frame: End of Treatment (≤2 days of last dose) andEnd of Study (Day 56±3 days)

  7. Time of the first mycological recurrence in the mITT population

    Time frame: Day1 through End of Study (Day 56±3 days

  8. Number of Participants With Adverse Events and severity

    Time frame: Day1 through End of Study (Day 56±3 days)

07

Study locations

1 site
  • The First Affiliated Hospital Of University Of South China
    Hengyang, Hunan 421001, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Nov 2025, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2023
First posted
Jan 8, 2024
StartActual
Apr 27, 2024
Primary completionActual
Nov 7, 2025
CompletionActual
Nov 7, 2025
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06194201
Responsible party
Sponsor
First posted
Jan 8, 2024
Start date
Apr 27, 2024
Primary completion
Nov 7, 2025
Completion
Nov 7, 2025
Last update
Sep 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion